Evidence map›Paper›PMID 27001119›Full record

ArticleThe pharmacogenomics journal2017

Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.

S Mahurkar, M Moldovan, V Suppiah, M Sorosina, F Clarelli, G Liberatore, S Malhotra, X Montalban, A Antigüedad, M Krupa and 15 more

Abstract read
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Zfp697 is an RNA-binding protein that regulates skeletal muscle inflammation and remodeling.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Involvement of Genetic Factors in Multiple Sclerosis.Frontiers in cellular neuroscience · 2020
    Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 13 institutions in 3 countries.

S MahurkarSchool of Pharmacy and Medical Sciences and Sansom Institute for Health Research, University of South Australia, Frome Road, Adelaide, South Australia, Australia.
M MoldovanSouth Australian Health &Medical Research Institute and Sansom Institute for Health Research, University of South Australia, Adelaide, South Australia, Australia.
V SuppiahSchool of Pharmacy and Medical Sciences and Sansom Institute for Health Research, University of South Australia, Frome Road, Adelaide, South Australia, Australia.
M SorosinaLaboratory of Genetics of Complex Neurological Disorders, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.
F ClarelliLaboratory of Genetics of Complex Neurological Disorders, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.
G LiberatoreLaboratory of Genetics of Complex Neurological Disorders, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.
S MalhotraServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Receca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
X MontalbanServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Receca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
A AntigüedadServicio de Neurología, Basurto Hospital, Bilbao, Spain.
M KrupaFlinders University and Medical Centre, Adelaide, South Australia, Australia.
V G JokubaitisDepartment of Medicine (Royal Melbourne Hospital), The University of Melbourne, Parkville, Victoria, Australia.
F C McKayCentre for Immunology and Allergy Research, Westmead Millennium Institute, University of Sydney, Sydney, New South Wales, Australia.
P N GattCentre for Immunology and Allergy Research, Westmead Millennium Institute, University of Sydney, Sydney, New South Wales, Australia.
M J Fabis-PedriniWestern Australian Neuroscience Research Institute, Centre for Neuromuscular and Neurological Disorders, University of WA, Nedlands, Western Australia, Australia.
V MartinelliLaboratory of Genetics of Complex Neurological Disorders, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.
G ComiLaboratory of Genetics of Complex Neurological Disorders, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.
J Lechner-ScottHunter Medical Research Institute, The University of Newcastle, Newcastle, New South Wales, Australia.
A G KermodeWestern Australian Neuroscience Research Institute, Centre for Neuromuscular and Neurological Disorders, University of WA, Nedlands, Western Australia, Australia.
M SleeFlinders University and Medical Centre, Adelaide, South Australia, Australia.
B V TaylorMenzies Institute for Medical Research, University of Tasmania, Tasmania, Australia.
K VandenbroeckNeurogenomiks Group, Universidad del País Vasco (UPV/EHU), Leioa, Spain.
M ComabellaServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Receca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
F M BoneschiLaboratory of Genetics of Complex Neurological Disorders, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.
Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene)
C KingSchool of Pharmacy and Medical Sciences and Sansom Institute for Health Research, University of South Australia, Frome Road, Adelaide, South Australia, Australia.
San Raffaele University of Rome · ITUniversity of South Australia · AUFlinders Medical Centre · AUUniversitat Autònoma de Barcelona · ESUniversity of Sydney · AUAchucarro Basque Center for Neuroscience · ESHospital de Basurto · ESHunter Medical Research Institute · AUMurdoch University · AUPerron Institute for Neurological and Translational Science · AUThe Royal Melbourne Hospital · AUUniversity of Tasmania · AUVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Up to 50% of multiple sclerosis (MS) patients do not respond to interferon-beta (IFN-β) treatment and determination of response requires lengthy clinical follow-up of up to 2 years. Response predictive genetic markers would significantly improve disease management. We aimed to identify IFN-β treatment response genetic marker(s) by performing a two-stage genome-wide association study (GWAS). The GWAS was carried out using data from 151 Australian MS patients from the ANZgene/WTCCC2 MS susceptibility GWAS (responder (R)=51, intermediate responders=24 and non-responders (NR)=76). Of the single-nucleotide polymorphisms (SNP) that were validated in an independent group of 479 IFN-β-treated MS patients from Australia, Spain and Italy (R=273 and NR=206), eight showed evidence of association with treatment response. Among the replicated associations, the strongest was observed for FHIT (Fragile Histidine Triad; combined P-value 6.74 × 10

Indexed as

AdultAustraliaFemaleGenetic MarkersGenome-Wide Association StudyGenotypeHumansInterferon-betaItalyMaleMultiple SclerosisPolymorphism, Single NucleotideSpainGenetic MarkersInterferon-beta

Identifiers

PMID27001119
OpenAlexW2305738422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.